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In this work matrix based nanoparticulate polymer systems have been designed
using the diacrylate derivative of the well-known biocompatible polymer,
poly(ethylene glycol) (PEG). This has been crosslinked using bifunctional (ethyleneglycol
dimethacrylate) and tetrafunctional (pentaerythritol tetraacrylate) crosslinkers in varied
concentrations (10-90%) to result in a polymeric network. The crosslinked polymers thus
obtained were characterized by spectroscopic techniques (NMR and FTIR) and then
prepared nanoparticles by the nanoprecipitation technique. Particle size analysis
showed sizes of ~150 nm (PDI < 1) (with tetrafunctional crosslinker) and ~300 nm (with
bifunctional crosslinker). Both the systems however showed unimodal narrow particle
size distributions with negative zeta potential values of -15.6 and -7.3 respectively.
Cytotoxicity of these formulations was evaluated by MTT assay showing non-cytotoxic
nature of these carrier systems. In vitro drug loading and release studies were carried
out using a model chemotherapeutic drug, methotrexate(MTX). These MTX loaded
nanoformulations have also been evaluated biologically with the help of in vivo studies
using radiolabeling techniques (with 99mTc radionuclide). The blood kinetics profile of
the formulations was studied on New Zealand Albino rabbits while the biodistribution
studies were performed on balb/c mice (with EAT tumours), which revealed a
hepatobiliary mode of elimination. These preliminary studies clearly demonstrated
the ability of these multifunctional crosslinkers to result in tight nanosized
networks with biocompatible polymers such as PEG and their potential to carry
chemotherapeutic drugs.
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TechnetiumBackground
The past few decades have seen a tremendous advancement in the area of drug deliv-
ery using polymeric particulate carrier systems for small and large molecules. En-
hanced medical treatments do not always require a stronger medicine/drug but a
better mechanism to deliver the drug. Crosslinked polymeric systems have shown
much interest owing to their potential applications for the entrapment and release of
multitude of pharmaceutically active molecules and drugs [1]. Nanoparticulate systems
are a great platform to alter and thereby help to improve the pharmacokinetic and
pharmacodynamic properties of various types of drug molecules [2–4].
Matrix based nanoparticulate polymeric systems offer unique advantages for polymer
based drug delivery systems (DDS) over polymer–protein conjugates [5], polymer–2014 Thukral et al.; licensee Springer. This is an Open Access article distributed under the terms of the Creative Commons
ttribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any
edium, provided the original work is properly credited.
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doubly hydrophilic block copolymers [12,13,33], dendrimers [15,16], and submicron-
sized particulates [17]. These offer tunable sizes from nanometers to several microme-
ters and a large surface area for multivalent bioconjugation. They also have an interior
network for the incorporation of therapeutics such as drugs, proteins, etc. Polymeric
networks with physically entrapped bioactive molecules such as drugs, proteins, carbo-
hydrates and DNA have been extensively investigated as targeted drug delivery carriers
for biomedical applications [18]. Crosslinked polymeric systems can be prepared by
chemical crosslinking of the polymeric matrices in the presence of various crosslinkers
such as ethyleneglycol dimethacrylate (EGDMA), polycaprolactone (PCL) diacrylate,
methyl methacrylate (MMA), divinyl benzene (DVB), pentaerythritol triacrylate (PETA),
pentaerythritol tetraacrylate, etc. The crosslinking agents play a pivotal role in the prep-
aration of nanoparticulate systems since various properties such as size, shape, struc-
ture, etc. depend on the type and concentration of the crosslinker used in the system.
Such crosslinked systems show higher stability for prolonged circulation in the blood-
stream owing to their chemically crosslinked structure. Their interior network acts as a
drug reservoir providing enhanced drug loading by physical entrapment relative to
non-crosslinked systems. The entrapment efficiency can be further enhanced by varying
the crosslink density which is determined by the number of crosslinks governed by the
type of crosslinker used for the preparation of the network. Drug encapsulation in these
crosslinked polymeric systems such as PEG based systems could be tailored by several
parameters, viz.-a-viz. the functionality of the crosslinker, the molecular weight of the
PEG derivative and the architecture of the PEG molecule (linear versus star shaped
PEG derivative). The improved drug loading efficiency of these systems augments the
bioavailability of the drug thereby reducing any undesired side effects [19]. This is un-
deniably a highly advantageous aspect while using anti-cancer drugs as their side effects
may result in compromised efficacy. Both biodegradable and biocompatible polymers
have been investigated to prepare crosslinked networks that can carry chemotherapeu-
tic drug payloads for therapeutic and delivery purposes. Cytarabine encapsulated chito-
san nanoparticles using sodium tripolyphosphate as a crosslinking agent have been
prepared that showed controlled release over a period of time [20,21]. Core-shell cross-
linked nanoparticles, having polycaprolactone core and polyethyleneglycol or poly
[2-(N,N-dimethylamine) ethyl methacrylate] shells have been investigated to encapsu-
late cisplatin and show cytostatic efficacies against a human ovarian adenocarcinoma
cell line [22,23]. Extensive research has been done utilizing poly(ethylene glycol)(PEG)
for drug delivery applications owing to its biocompatible nature. Cross-linked PEGs are
finding increasing application as carriers of chemotherapeutic agents be it in the form
of hydrogels [30,31] or in the form of copolymer micelles [32,14,34]. It was therefore
proposed to use PEG as the core polymer for our work in order to further exploit its
favorable attributes.
In this work we describe the synthesis and characterization of crosslinked PEG based
nanoparticles and explore their potential to be used as drug delivery carriers. We used
the acrylated derivative of polyethyleneglycol, i.e. polyethyleneglycol diacrylate(PEGDA)
as the main polymer and crosslinked it using bifunctional and tetra functional crosslin-
kers, ethyleneglycoldimethacrylate (EGDMA) and pentaerythritol tetraacrylate (PETRA)
respectively. The prepared nanoparticles were characterized by physico-chemical
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potential measurements. These were loaded with methotrexate as the model chemothera-
peutic agent and the drug loaded nanoparticles were then evaluated by in vitro and
in vivo techniques to investigate their cellular toxicity and blood kinetics. We have also in-
vestigated their biodistribution profile in murine tumour models and imaged their tumour
uptake by gamma scintigraphy post labeling with technetium-99m radioisotope (99mTc).
Methods
Materials
Polyethylene glycol diacrylate (PEGDA) (MW 575), Pentaerythritol tetraacrylare (PETRA)
and Ethyleneglycol dimethacrylate(EGDMA) were procured from M/s Sigma Aldrich,
USA. Azobis(isobutyro-nitrile)(AIBN) was procured from M/s SRL, Mumbai. Technetium-
99m was procured from Regional Center for Radiopharmaceuticals (Northern region),
Board of Radiation and Isotope Technology (BRIT), Department of Atomic Energy, India.
Infrared spectra (IR) were recorded by the KBr pellet method in the range of 4000 – 400
cm−1 on a Perkin Elmer Spectrum BX-II spectrophotometer. NMR measurements were
carried out on a Bruker 400 MHz system. Mass spectroscopic analysis was performed using
an Agilent 1100 System coupled with LC operation in ESI (Electro Spray Ionization) posi-
tive/negative mode. UV-Vis scanning was done on a UV-Vis spectrophotometer, ECIL,
India, as per reported literature [24]. Gamma ray spectrometer (type GRS23C)(Electronics
Cooperation of India Pvt. Ltd., India, was used for determining the amount of activity
(γ-emitter) in the samples. Gamma scintillation camera (HAWKEYE) was used for
imaging of animals.
Animal models for biological evaluation
Balb/c mice of either sex (weighing 25-30 g) with no prior drug treatment were used
for biodistribution studies and gamma imaging. Healthy, New Zealand Albino rabbits
(2.5-3 Kg) were employed for blood kinetics studies. All animal experiments and study
protocols were approved by the Committee for the Purpose of Control and Supervision
of Experiments on Animals (CPCSEA), Government of India, New Delhi.
Normal Balb/c mice, each weighing about 25-30 g, were inoculated with Ehrlich
Ascites Tumour (EAT). The EAT cells were maintained in the ascites form by serial
weekly passage. Exponentially growing cells were harvested and 10 ×106 (approx) cells
were injected subcutaneously in the right hind leg of the mice when a palpable tumour
in the volume range of 0.9 ± 0.1 cm3 was observed in 7-10 days. Mice and rabbits were
housed under conditions of controlled temperature of 22 ± 2°C and preserved on stand-
ard diet and water. All possible steps were taken to minimize the suffering of the ani-
mals at each stage of the experiment.
Synthesis of crosslinked nanoparticles by free radical thermal polymerization
The nanoparticles were prepared by free radical thermal polymerization using AIBN as
a thermal initiator. The reaction was carried out in a 3-necked round bottom flask
equipped with a condenser, thermometer, round bead and a nitrogen inlet. Required
amounts of the polymer (PEGDA), solvent (DMF) and the desired crosslinkers, PETRA
or EGDMA, were added to the round bottom flask as per Table 1, which was placed in
the water bath. As soon as the temperature of the water bath reached 70°C, AIBN was
Table 1 Synthesis of crosslinked nanoparticles by free radical thermal polymerization
Formulations PEGDA (% w/v) EGDMA (% w/v) PETRA (% w/v) AIBN (% w/w)
PE1 70 70 ----- 3
PE2 70 80 ----- 3
PE3 70 90 ----- 3
PP1 70 ----- 70 3
PP2 70 ----- 80 3
PP3 70 ----- 90 3
PE: EGDMA crosslinked PEGDA series; PP: PETRA crosslinked PEGDA series.
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perature of 70°C for 12 h. A white product precipitated out on addition of excess of
cold diethyl ether which was filtered using vacuum followed by thorough washing (2-3
times) with diethyl ether. The final product was air dried overnight before further
evaluation. Using the nanoprecipitation technique, nanoparticles of these crosslinked
systems were prepared after optimization of the polymer concentration so as to achieve
the least particle size.
The drug loading of PP1 was carried out using MTX as a model drug in 1:10 drug:
polymer ratio. The in vitro release profile was studied in PBS buffer (pH 7.4) and at pH
5.5 in acetate buffer. The percentage drug release was calculated using the equation:




‘t’ being the time at which the absorbance is measured and ‘t0’ the initial time.
Characterization of nanoparticles
Dynamic light scattering measurements were used to obtain values of average hyd-
rodynamic diameter in dilute dispersions at 25°C using a Malvern Zetasizer ZS 90
equipped with a He-Ne laser beam at a wavelength of 632.8 nm (scattering angle of 90°).
Prior to analysis, solutions were filtered through a Millex filter (pore size ≈ 0.45 μm) to
remove dust. The determination of diffusion coefficient was calculated by fitting the data
with the cumulants method and diameters were estimated by the Stokes–Einstein
equation, assuming a population of non-interactive spherical particles [25].
Cytotoxicity of nanoparticles
Cytotoxicity of the bare nanoformulations was determined using V79 fibroblast cells
and the anticancer activity of the drug loaded formulation was assayed against MCF-7
breast cancer cells by the MTT {3-4,4-dimethylthiazole-2-yl)-2,5-diphenyl-2H-tetrazolium
bromide} assay. Exponentially growing cells were plated in a 96-well microtitre plate at a
uniform cell density of 10,000 cells/well, 24 h prior to treatment. Cells were treated with
varying concentrations of the formulations (10-1000 μM) for different time intervals
(12-72 h) and MTT assays were performed in triplicate. At the end of the treatment
the treated cells were incubated with MTT at a final concentration of 0.5 mg/ml for
2 h at 37°C and the medium was removed. After specified time intervals (12,24,48, 72
h) the cells were lysed and the formazan crystals were dissolved using 150 μl of
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630 nm). Mitochondrial activity was expressed as percentage of viability compared to
negative control. Percentage of viability = [OD(570 nm-630 nm)test product/OD(570 nm-
630 nm)negative control] × 100.
Radiolabeling of nanoformulations
Both the drug loaded and unloaded formulations were labeled with 99mTc by the direct
labeling method. Briefly, 100 μL of sterile sodium pertechnetate in saline (containing
approx. 74-110 MBq of 99mTcO4
− obtained by solvent extraction method from Molyb-
denum) was added to 100 μL (1 mg/mL) of each formulation followed by addition of
50 μL stannous chloride (2 mg/mL in 10% glacial acetic acid); pH was adjusted to 6.5
using 0.1 M NaOH, and the resulting solution was incubated at 37˚C for 15 mins. The
labeled formulations, thus obtained, were stored in sterile shielded vials for subsequent
studies. The radiolabeling efficiency was determined by ascending instant thin layer
chromatography (ITLC) as reported in detail elsewhere [26].
In vitro human serum stability
The metabolic stability of the nanoformulations was ascertained in vitro in freshly col-
lected human serum from healthy volunteers. Human serum was prepared by allowing
blood collected from healthy human volunteers to clot for 1hr at 37°C in a humidified
incubator maintained at 5% carbon dioxide, 95% air. The samples were then centri-
fuged at 400 g and the serum was filtered through a 0.22 μm filter into sterile plastic
culture tubes. 100 μL of 99mTc labeled formulations were incubated respectively in 900
μL of this serum (in duplicate) at 37°C and analyzed to check for any dissociation of
the complex by ITLC using silica gel strips and 0.9% NaCl aqueous solution (saline) as
developing solvent. The change in labeling efficiency was monitored over a period of
24 hr.
In vivo evaluation
Blood clearance and plasma protein binding studies in rabbits
Blood clearance of 99mTc-labeled nanoformulations was studied in healthy New Zealand
Albino rabbits weighing 2.5-3.5 kg (n = 3). 300 μL of the individual radiolabeled com-
plexes (10 MBq) were administered intravenously through the dorsal ear vein. Blood
samples were withdrawn from the other ear vein at different time intervals ranging
from 5 mins-24 h. Persistence of activity in the circulation was calculated as percentage
injected dose per whole blood, assuming total blood volume as 7% of the body weight.
The radioactivity of the precipitate and supernatant was measured in a well-type
gamma spectrometer.
Using the above blood samples, plasma was separated out by centrifugation, and the
plasma proteins were precipitated by addition of 10% trichloroacetic acid (TCA). The
radioactivity of the precipitate and supernatant was measured in a well-type gamma
spectrometer.
Biodistribution in mice
Tumour bearing mice were administered 100 μL (3.7 MBq) of 99mTc labeled formula-
tions, respectively, through the tail vein(i.v.). At 1, 2, 4 and 24 h post injection, the
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weighed tubes. The mice were then dissected and different organs (heart, lungs, liver,
spleen, kidneys, stomach, intestine, bone, muscle (normal and tumour) and brain) were
removed, weighed and their radioactive counts taken with the help of a gamma coun-
ter. Uptake of the radiolabeled compound into each organ was measured per gram of
the tissue/organ and expressed as percentage injected dose per gram organ weight. The
radioactivity remaining in the tail (point of injection) was also measured and taken into
account while calculating the radioactivity.
Gamma scintigraphy
The tumour bearing mice were administered 100 μl (3.7MBq) of 99mTc labeled formu-
lations, respectively (i.v.), through the tail vein and gamma imaging was performed at
different time intervals using a planar gamma camera equipped with a collimator.
Results and discussion
Several criteria including control over biological, chemical and physical properties are
required for the design and development of an effective nanoparticle based drug carrier
system for in vivo biomedical applications. These may include non-toxicity to cells, sta-
bility for prolonged circulation in blood stream, high loading efficiency and controllable
release of therapeutics in addition to elimination of empty carrier after drug release.
With this view, an effort was made to design a nanoparticulate system based on the
biocompatible PEG matrix, using PEGDA, that contains crosslinkable sites in the poly-
mer backbone. Crosslinked nanoparticles of polyethylene glycol were prepared by free
radical polymerization and crosslinking of PEGDA chains with EGDMA and PETRA in
the presence of AIBN. Owing to its ease of usage we opted for the free radical thermal
polymerization technique using AIBN as the thermal initiator. The minimum and max-
imum concentrations for forming stable particles were ranging from 70-90% for
EGDMA and PETRA. Use of crosslinkers lower than 70% resulted in incomplete cross-
linking while concentrations greater than 90% led to precipitation.
IR spectroscopy was performed to confirm the formation of crosslinks between PEG
and the crosslinking monomers. The IR spectra of the reactants (PEGDA, EGDMA,
PETRA) and the product (PEGDA-based network) were compared for changes in vital
peaks (Figure 1a,b). The FTIR spectra of PEGDA, EGDMA and PETRA had typical ab-
sorption bands of medium intensity at about 1640 cm−1 corresponding to alkenes. This
band completely disappeared in the spectra of the networks owing to the consumption
of – C = C – bonds during the crosslinking reaction. Also, the wavenumber of the car-
bonyl stretching resonance (C =O) of the acrylate moiety shifts from 1720 to 1730 cm−1
on reaction. These were corroborated by the NMR spectroscopy results. The 1H NMR
spectra of the crosslinked structures showed a complete disappearance of the peaks in the
5.5 – 6.5 ppm region corresponding to acrylate terminal functionalities of PEGDA,
EGDMA and PETRA. These results indicated that the – C =C – double bonds were
successfully incorporated into the PEG based network.
The average particle size of the prepared crosslinked nanoparticulate formulations
was found to be in the range of 130 nm to 349 nm depending on the concentration
and type of the polymeric system (Table 2). It was observed that the polymeric formula-
tions prepared using PETRA crosslinker (PP series) were found to give relatively lower















Table 2 Particle size and zeta potential measurements
Compound PE Compound PP
Parameters Size (nm) PDI Zeta potential (mV) Parameters Size (nm) PDI Zeta potential (mV)
PE 1 349.0 1.00 −8.85 PP 1 130.3 1.00 −21.5
PE 2 305.0 0.48 −7.34 PP 2 154.1 1.00 −15.6
PE 3 277.5 0.51 −7.99 PP 3 211.8 0.06 −13.5
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the systems showed unimodal narrow particle size distributions with negative zeta po-
tential values (Additional file 1: Figure S1 and Figure S2). The average particle size of
the system consisting of EGDMA as a crosslinking agent was found to be in the range
of 277 nm to 349 nm with varying concentration of the system while the particle size
of the formulations varied from 130 nm to 211 nm when PETRA was used as the
crosslinking agent. The zeta potential values hovered around -8 mV in the PE series
whereas they varied from -13 to -21 mV in the PP series, a favorable aspect for in vivo
applications. These results showed that as the number of the functional moiety, which
is bulky acrylate group, increased from 2 to 4, the particle size of the formulations de-
creased by about 45-60%. This suggested that the number of the crosslinkable func-
tional moieties strongly influences the formation of stable particles. Also, within the PE
series, the particle size decreased with increasing concentration of polymer and cross-
linker from PE1 to PE3, while in the PP series, the particle size increased from PP1 to
PP3. That is, the smaller the number of the crosslinkable functional moieties in the
crosslinking agent, the higher the concentration of crosslinking agent was needed for
the formation of smaller particles. On the other hand, the larger the number of the
crosslinkable functional moieties, the lower the concentration of it was needed. Similar
results have been reported by other groups for the formation of crosslinked microspheres
[27]. Based on these results PP1 was chosen as the model system for further drug loading
experiments. But before that, it was imperative to check whether this carrier system was
itself a source of toxicity to the in vivo system or not.
The in vitro cytotoxicity studies of this system were done by the MTT assay. The for-
mulation was tested for its ability to induce cytotoxicity in V79 fibroblast cells using an
assay of mitochondrial activity (MTT assay). After 24, 48, and 72 h of exposure, viability
was assessed on the basis of cellular conversion of MTT into a formazan product. A
plot of percentage viability against the concentration revealed a decrease in the mi-
tochondrial activity of the nanoformulation with increased concentration of upto
1000 μM (Figure 2). Even after 48 h of incubation, the formulations appeared to be
non-toxic upto very high concentrations of almost 800 μM. These results suggested
that the PETRA crosslinked nanoparticles of PEGDA are nontoxic to normal cells
which confirmed their safety for non-cancerous cells. Of these PETRA crosslinked for-
mulations, PP1, which formed the smallest size of nanoparticles, was taken as the
matrix based system for further drug loading and biological evaluations. The anticancer
activity of the free MTX and MTX loaded PP1 (M-PP1) was studied on MCF-7 breast
cancer cells. MTT assay showed that both the free drug and the drug loaded nanofor-
mulation could significantly suppress MCF-7 cell proliferation in a dose and time
dependent manner (Figure 3a-c). While at the same concentration, the MTX loaded
PP1 showed significantly higher inhibition rates against MCF-7 cells compared to free
Figure 2 In vitro cytotoxicity of PETRA crosslinked PEGDA formulations; PP 1, PP 2 and PP 3 after
48 h of incubation.
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mulation (U-PP1) was taken as the control and it was found to show negligible effect
on cell viability (Figure 3). Thus the cytotoxicity of the MTX loaded nanoformulations
was confirmed to be because of the encapsulated MTX.
Polymeric nanoparticles can be loaded with drugs using three major strategies viz.-a-
viz. covalent attachment of the drug to the particle surface or to the polymer prior to
preparation, adsorption of the drug to a preformed carrier system, and incorporation of
the drug into the particle matrix during particle preparation [28]. However, the import-
ant condition is that the bioactivity of therapeutic agents must remain intact during thisFigure 3 Anticancer activity of MTX loaded PP1 in MCF-7 cell line at (a) 12 h (b) 24 h (c) 48 h.
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capsulate MTX. By optimization of the nanoprecipitation conditions our PEG based
crosslinked matrix readily self assembled into reproducible polymeric micelles actively
encapsulating the MTX particles in solution. The MTX loaded dispersions (MTX-PP1)
displayed a yellow colour as compared to the almost translucent unloaded ones
(Figure 4 inset). In order to study the in vitro release of the incorporated drug, mem-
brane diffusion techniques are often used. In these cases, drug release follows more
than one mechanism. In case of release from the surface of the nanoparticles, the
adsorbed drug quickly dissolves on contact with the release medium. The entrapped
drug then gets gradually released by the diffusion mechanism. Loading and release
characteristics of methotrexate from these particles was studied at pH 5.5 and 7.4 using
these membrane diffusion techniques. The unloaded drug and the organic solvent
DMSO were removed by dialysis against distilled water. Drug loading content and drug
loading efficiency was then determined spectrophotometrically at 303 nm. The MTX
loaded PP1 was found to have a drug loading content of 7.68% and an encapsulation ef-
ficiency of 65.8%. The drug release profile of free MTX and MTX loaded polymeric
nanoparticles over a 72 h study period is shown in Figure 4. Free MTX was completely
released within 6 h at pH 5.5 and within 7 h at pH 7.4 while after encapsulation in the
PEG based matrix the in vitro release pattern of MTX showed a drastic change and
only 20-25% of the drug could be released from the matrix bound particles within the
same duration. This clearly indicates the absence of any free unloaded MTX in the pre-
pared polymeric particle solutions as no burst release effect could be seen. The release
studies of the MTX-loaded particles indicate a biphasic release pattern, similar for both
the pH conditions. Almost 40-50% of the drug was released from the particles within
the first 24 h. Thereafter, a very slow drug release pattern was observed and a cumula-
tive 50-65% MTX release was seen over a period of 72 h (the period of study) owing to
the release of the entrapped drug by the diffusion mechanism. This could be an advan-
tageous feature of this MTX-loaded polymeric system where initial fast drug release




















Free MTX at pH 7.4
Drug Loaded PP at pH5.5
Drug Loaded PP at pH7.4
Free MTX at pH 5.5
Figure 4 In vitro Drug release profile of free MTX and MTX loaded PETRA crosslinked PEGDA formulation
over 72h.
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the labeling parameters such as pH, concentration of reducing agents (SnCl2), tem-
perature, etc. were standardized to achieve the maximum labeling efficiency [29]. The
proteolytic degradation of the radiolabeled formulations was determined in human serum
in vitro. ITLC analysis of the human serum revealed that the 99mTc-nanoformulations
remained sufficiently stable during incubation at 37°C with human serum. A maximum of
8% of radioactivity degraded after 24 h of incubation advocating a high in vitro stability of
almost 92% of the nanoformulation for upto 24 h.
A comparative evaluation of the blood clearance profile of the radiolabeled drug and
nanoformulation in normal rabbits showed a biphasic mode of clearance (Figure 5).
The radiolabeled drug, 99mTc-MTX demonstrated a quicker washout from the blood in
a biphasic manner with a fast and slow half-life time of 35 mins and 17 h respectively,
and only 25% of the injected dose remaining after 2 h of injection. However, the radi-
olabeled nanoformulation, 99mTc-MTX-PP1, exhibited relatively slower clearance in a
somewhat biphasic pattern from blood circulation as expected for a matrix based sys-
tem with almost 50% of the injected labeled compound remaining in blood 1 h post in-
jection. The rest remained in circulation for upto 24 h and was gradually cleared from
systemic circulation owing to the small size of the formulations and also perhaps not
being readily taken up by the reticuloendothelial system (RES). 75-85% of the nanopar-
ticulate carriers were eliminated from the blood circulation within 24 h. The t½ (fast)
for the nanoformulation was found to be 45 mins, and the t½(slow) was 27.5 h respect-
ively. At every time point the amount of the labeled MTX-PP1 conjugate in blood was
more than the neat drug, thus suggesting longer blood retention, as also indicated by
the half life-time values.
Protein binding studies showed a difference in the plasma protein binding of 99mTc-
MTX as compared to its encapsulated form. Binding of 99mTc-MTX to plasma proteins
was only 68% whereas it was 54-58% in the case of 99mTc-MTX-PP1 nanoformulation
probably because of the PEG based matrix.
Figure 6 represents complete tissue distribution after intravenous administration of
99mTc-labeled MTX-PP1 and results are expressed as percentage of the injected dose of





















Figure 5 Blood clearance profile of 99mTc labeled MTX and PETRA crosslinked PEGDA formulation
(PP1) over a period of 24 h.
Figure 6 Biodistribution of MTX loaded PETRA crosslinked PEGDA formulation (PP1) over a period
of 24 h.
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mice showed remarkable localization in tumour muscles (Figure 6) which could be well
differentiated as compared to the negligible uptake in the normal muscles. This was
also corroborated by the tumour-to-blood ratios that improved at increasing time
points (Figure 7). A low uptake of radioactivity was observed in the stomach at all the
time points(less than 2% ID/g) indicating a minimal in vivo decomposition of the radi-
olabeled nanoformulation to form the free 99mTcO4
−. The radiolabeled formulation ac-
cumulated to a higher level in the liver and kidneys at early time points after injection.
The route of excretion of both the compounds was therefore perceived to be hepato-
biliary. This clearly indicated that these crosslinked nanoparticulate carriers eventually
get eliminated from the body.
The relative tumour uptake of the 99mTc labeled formulations compared to the contra-
lateral normal muscle (tumour:muscle ratio) in balb/c mice is shown in Figure 7. The
MTX loaded formulation showed high uptake in tumour muscles. This uptake helped to
clearly delineate the tumour from the rest of the normal muscle which was also corrobo-


















Figure 7 The relative tumour uptake of PETRA crosslinked PEGDA formulation (PP1) compared to
the contralateral normal muscle (tumour:muscle ratio) over a period of 24 h.
Figure 8 Whole-body γ-scintigraphic image of balb/c mice with subcutaneous EAT tumor above the
right hind leg injected with 99mTc labeled PETRA crosslinked PEGDA formulation.
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Synthesis and characterization of the PEG based nanoparticles has been described in
this study. These were successfully loaded with the anticancer drug, MTX, to evaluate
their potential for anticancer drug delivery. The in vitro drug release pattern of the
drug showing an initial fast release within the first 6 h followed by an eventual gradual
release over 72 h could well be exploited for therapy regimes spread out over long du-
rations thereby reducing the frequency of drug uptake. For clinical relevance, in
addition to obtaining low non-specific uptake in healthy cells, sufficient uptake must
occur in tumour cells to cause cell death. The MTT assay on fibroblast cells (healthy
cells) and MCF-7 cells(human carcinoma) proved the clinical significance of these
MTX loaded PETRA crosslinked PEGDA nanoparticles. The avid tumour uptake of the
99mTc-labeled nanoformulation and its gradual tumour washout demonstrated its use
both as a tumour diagnostic agent as well as a therapeutic agent for cancer therapy.
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models can give significant information on the therapeutic efficacy of these particles,
which can form part of our future research work. Also, labeling of these crosslinking
polymeric systems with gadolinium as an imaging marker can also form part of our fu-
ture studies so imaging with MRI can be utilized. The investigations carried out as part
of this work gave adequate evidence that the prepared crosslinked polymeric nanoparti-
culate formulations may be vital nanoparticulate carriers of chemotherapeutic drugs
such as methotrexate, for potential drug delivery applications.
Additional file
Additional file 1: Figure S1 and Figure S2. Gives details of the size and zeta potential measurements of EGDMA
and PETRA crosslinked PEGDA formulations respectively.
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